East China Pharmaceutical (000963.SZ): Clinical trial of injectable HDM2012 approved.

Zhixin Finance APP News, East China Pharmaceuticals (000963.SZ) announced that its wholly-owned subsidiary Hangzhou Zhongmei East China Pharmaceuticals Co., Ltd. ("Zhongmei East China") has received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration (NMPA). The application for the clinical trial of injection HDM2012 (late-stage solid tumors) submitted by Zhongmei East China has been approved.